Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid

Annals of Plastic Surgery

Volumn 63, Issue 1, 2009, Pages 94-99

  Zhang, Guo You ^a   Gao, Wei Yang ^a   Li, Xuan ^b   Yi, Cheng Gang ^c   Zheng, Yan ^c   Li, Yang ^c   Xiao, Bo ^c   Ma, Xian Jie ^c   Yan, Li ^c   Lu, Kai Hua ^c   Han, Yan ^c   Guo, Shu Zhong ^c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Second People's Hospital of Hefei   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Camptothecin; Collagen; Fibrosis; Keloid; Topoisomerase I; Wound healing

Indexed keywords

CAMPTOTHECIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CELL METABOLISM; CELL VIABILITY; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; KELOID; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CAMPTOTHECIN; COLLAGEN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; FIBROBLASTS; HUMANS; KELOID; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; WOUND HEALING; YOUNG ADULT;

EID: 67651229520     PISSN: 01487043     EISSN: None     Source Type: Journal    
DOI: 10.1097/SAP.0b013e3181872775     Document Type: Article

References (43)

1. Linares HA, Larson DL, Willis-Galstaun BA. Historical notes on the use of pressure in the treatment of hypertrophic scars or keloids. Burns. 1993;19: 17-21. (Pubitemid 23059384)
2. Berman B, Bieley HC. Keloids. J Am Acad Dermatol. 1995;33:117-123.
3. Rockwell WB, Cohen IK, Ehrlich HP. Keloids and hypertrophic scars: a comprehensive review. Plast Reconstr Surg. 1989;84:827-837.
4. Kischer CW, Brody GS. Structure of the collagen nodule from hypertrophic scars and keloids. Scan Electron Microsc. 1981;3:371-376. (Pubitemid 11016022)
5. Kischer CW, Thies AC, Chvapil M. Perivascular myofibroblasts and microvascular occlusion in hypertrophic scars and keloids. Hum Pathol. 1982;13: 819-824. (Pubitemid 12009536)
6. Kischer CW, Shetlar MR. Collagen and mucopolysaccharides in the hypertrophic scar. Connect Tissue Res. 1974;2:205-213.
7. Ladin DA, Garner WL, Smith DJ Jr. Excessive scarring as a consequence of healing. Wound Repair Regen. 1995;3:6-14.
8. Datubo-Brown DD. Keloids: a review of the literature. Br J Plast Surg. 1990;43:70-77.
9. Niessen FB, Spauwen PH, Schalkwijk J, et al. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104:1435-1458. (Pubitemid 29466295)
10. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today. 1998;4:19-24.
11. Stewart L, Ireton GC, Parker LH, et al. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 1996;271: 7593-7601. (Pubitemid 26107037)
12. Pommier Y, Pourquier P, Fan Y, et al. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1998;1400:83-106. (Pubitemid 28475097)
13. Fan Y, Weinstein JN, Kohn KW, et al. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J Med Chem. 1998;41:2216-2226. (Pubitemid 28285723)
14. Bendixen C, Thomsen B, Alsner J, et al. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry. 1990;29:5613-5619. (Pubitemid 20202289)
15. Darzynkiewicz Z, Bruno S, Del Bino G, et al. The cell cycle effects of camptothecin. Ann NY Acad Sci. 1996;803:93-100.
16. Giovanella BC, Stehlin JS, Wall ME, et al. DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046-1048. (Pubitemid 20010531)
17. Husain I, Mohler JL, Seigler HF, et al. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res. 1994;54:539-546. (Pubitemid 24053198)
18. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer. 1998;34:1500-1508. (Pubitemid 28446329)
19. Takimoto CH, Wright J, Arbuck SG. Clinical applications of the camptothecins. Biochim Biophys Acta. 1998;1400:107-119.
20. Beran M, Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin Oncol. 1998;35:26-31.
21. Czuwara-Ladykowska J, Makiela B, Smith EA, et al. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Arthritis Res. 2001;3:311-318. (Pubitemid 32821525)
22. Miltyk W, Karna E, Palka JA. Prolidase-independent mechanism of camptothecin- induced inhibition of collagen biosynthesis in cultured human skin fibroblasts. J Biochem. 2007;141:287-292. (Pubitemid 46775765)
23. Rudnicka L, Czuwara J, Barusińska A, et al. Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis. Ann NY Acad Sci. 1996;803:318-320. (Pubitemid 27058003)
24. Zhang GY, Yi CG, Li X, et al. Inhibition of vascular endothelial growth factor expression in keloid fibroblasts by vector-mediated vascular endothelial growth factor shRNA: a therapeutic potential strategy for keloid. Arch Dermatol Res. 2008;300:177-184.
25. Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989;49:4435-4440. (Pubitemid 19208340)
26. Ladin DA, Hou Z, Patel D, et al. p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen. 1998;6:28-37. (Pubitemid 128656988)
27. Saed GM, Ladin D, Olson J, et al. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strand conformational polymorphism and DNA sequencing. Arch Dermatol. 1998;134:963-967. (Pubitemid 28385318)
28. Yoshimoto H, Ishihara H, Ohtsuru A, et al. Overexpression of insulin-like growth factor-1 (IGF-I) receptor and the invasiveness of cultured keloid fibroblasts. Am J Pathol. 1999;154:883-889. (Pubitemid 29122607)
29. Ishihara H, Yoshimoto H, Fujioka M, et al. Keloid fibroblasts resist ceramideinduced apoptosis by overexpression of insulin-like growth factor I receptor. J Invest Dermatol. 2000;115:1065-1071. (Pubitemid 32037452)
30. Sayah DN, Soo C, Shaw WW, et al. Downregulation of apoptosis-related genes in keloid tissues. J Surg Res. 1999;87:209-216. (Pubitemid 30000588)
31. Chodon T, Sugihara T, Igawa HH, et al. Keloid-derived fibroblasts are refractory to Fas-mediated apoptosis and neutralization of autocrine transforming growth factor-beta1 can abrogate this resistance. Am J Pathol. 2000;157:1661-1669. (Pubitemid 30943223)
32. Cohen IK, Peacock EE. Keloids and hypertrophic scars. In: McCarthy JG, ed. Plastic Surgery. Philadelphia: WB Saunders; 1990:732-747.
33. Ala-Kokko L, Rintala A, Savolainen ER. Collagen gene expression in keloids: analysis of collagen metabolism and type I, III, IV, and V procollagen mRNAs in keloid tissue and keloid fibroblast cultures. J Invest Dermatol. 1987;89:238-244. (Pubitemid 17126576)
34. Uitto J, Perejda AJ, Abergel RP, et al. Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid fibroblasts. Proc Natl Acad Sci USA. 1985; 82:5935-5939. (Pubitemid 16218877)
35. Shykind BM, Kim J, Stewart L, et al. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev. 1997;11:397-407. (Pubitemid 27079916)
36. Merino A, Madden KR, Lane WS, et al. DNA topoisomerase I is involved in both repression and activation of transcription. Nature. 1993;365:227-232. (Pubitemid 23282081)
37. Douvas A. Does Scl-70 modulate collagen production in systemic sclerosis? Lancet. 1988;2:475-477. (Pubitemid 18199825)
38. Bugreev DV, Vasyutina EL, Kolocheva TI, et al. Interaction of human DNA topoisomerase I with specific sequence oligodeoxynucleotides. Biochimie. 1998;80:303-308. (Pubitemid 28291163)
39. Huang TT, Wuerzberger-Davis SM, Seufzer BJ, et al. NF-kappaB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J Biol Chem. 2000;275:9501-9509.
40. Kouba DJ, Chung KY, Nishiyama T, et al. Nuclear factor-kappa B mediates TNF-alpha inhibitory effect on alpha 2(I) collagen (COL1A2) gene transcription in human dermal fibroblasts. J Immunol. 1999;162:4226-4234. (Pubitemid 29314811)
41. Rippe RA, Schrum LW, Stefanovic B, et al. NF-kappaB inhibits expression of the alpha1(I) collagen gene. DNA Cell Biol. 1999;18:751-761. (Pubitemid 29504189)
42. Rosales C, Juliano R. Integrin signalling to NF-kappa B in monocytic leukemia cells is blocked by activated oncogenes. Cancer Res. 1996;15:2302-2305. (Pubitemid 26154078)
43. Palka JA, Phang JM. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptor. J Cell Biochem. 1997;67:166-175.